Targeting cancer metabolism
Cancer cells are addicted to glucose and glutamine, which enables them to generate the energy and macromolecule synthesis intermediates to support their growth...
List view / Grid view
Articles
The importance of adequately triaging hits from HTS campaigns
High throughput screening (HTS) continues to be employed in drug discovery as the primary source of identifying chemical starting points for drug discovery and tool compounds for chemical biology, respectively. Although small molecule drug discovery efforts have focused largely upon enzyme, receptor and ion-channel targets, there has been an increase…
Investigation of venom use in stem cell differentiation
Stem cells differentiate to form more than 200 specialised cells, including erythroid bodies, haematopoietic cells, myogenic cells, neural cells, signalling cells and structural cells, such as hepatocytes. Differentiation of stem cells triggers a number of variable changes in the cell, such as membrane potential, responsiveness to signal, metabolic activities, and…
Human pluripotent stem cell-derived cardiomyocytes in drug discovery and development
Procedures for cardiac differentiation of human pluripotent stem cells (hPSCs) have greatly improved over the past few years. The facilitated derivation of hPSC-cardiomyocytes has enabled the thorough assessment of their physiology and manipulation of their properties. Moreover, patient-specific hPSCs generated through cellular reprogramming allow for cardiac disease modelling, discovery of…
Drug Target Review – Issue #2 2015
10 June 2015 | By Drug Target Review
Included in this issue: Drug Discovery, Screening, Hit-to-Lead, Antibodies, Stem Cells, Kinases and much more...
Stem Cells In-Depth Focus 2015
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
This Stem Cells In-Depth Focus features articles on stem cell-derived cardiomyocytes, and their use in drug discovery and development, as well as a look at how venom could be used in stem cell differentiation...
Screening In-Depth Focus 2015
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
In this Screening In-Depth Focus, high throughput screening is the topic focused on by Kenji Schorpp and Kamyar Hadian, Institute of Molecular Toxicology and Pharmacology, and Sheraz Gul, Fraunhofer Institute for Molecular Biology and Applied Ecology. They discuss the importance of the technique in drug discovery today as well as…
Stem cells discoveries: Arming scientists with the tools they need
10 June 2015 | By Molecular Devices
Molecular Devices discusses stem cells research and the company’s latest technological advancements in this exciting field...
Academic drug discovery in neurodegeneration; a new approach to an ageing problem
Dementia is a global crisis with 76 million people worldwide expected to be living with the condition by 2030. Current symptomatic treatments provide modest improvements in cognition but disease-modifying therapies for diseases like Alzheimer’s – the most common cause of dementia – do not yet exist.
True screening for immunology: transforming science with a practical tool for large-scale discovery
10 June 2015 | By IntelliCyt Corporation
The immune system plays a vital role in keeping us alive but also participates in many diseases adversely affecting quality of life across the globe. It can be over activated, leading to a variety of inflammation and autoimmune diseases, or suppressed, leading to a vast array of diseases from AIDS…
A new dawn in academic and pharma collaboration – a UK perspective
Academia and pharma have always been uneasy bedfellows. There has in the past been tension between both caused by a range of issues that neither party was willing to try and resolve. However, there is a new impetus to solve these issues as both parties have started to realise that…
From hype to hope: challenging the norm in lead discovery
From the beginning of time in the drug discovery world, the integration of disciplines has driven the identification of new lead molecules. Chemists, pharmacologists and biologists work together to understand a disease state and how to perturb that state back towards a normal healthy condition. However, in the early days…
Developing antibody therapeutics
Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…
Novel approaches to targeting protein tyrosine kinases
Protein kinases, a diverse group of cellular enzymes, play fundamental roles in maintaining normal cellular functions such as growth, cell cycle control, proliferation, differentiation, migration, cellular survival and apoptotic induction.
Immune checkpoint inhibitors: targets on the horizon
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...